Histone H3.5 (H3.5) is a newly identified histone variant highly expressed in the human testis. We have reported the crystal structure, instability of the H3.5 nucleosome and accumulation around transcription start sites, mainly in primary spermatocytes, but its role in human spermatogenesis remains poorly understood. Testicular biopsy specimens from 30 men (mean age: 35 years) with non-obstructive azoospermia (NOA) who underwent microdissection testicular sperm extraction and 23 men with obstructive azoospermia (OA) were included. An H3.5-specific mouse monoclonal antibody recognizing an H3.5-specific synthetic peptide was generated, and immunohistological staining for H3.5 and proliferating cell nuclear antigen (PCNA) was performed on Bouin's solution-fixed sections. Expression and localization of H3.5 were compared with patient background, germinal stage, and PCNA expression. In testes of patients with normal spermatogenesis, differentially expressed H3.5 was specifically localized in either spermatogonia or preleptotene/leptotene-stage primary spermatocytes, especially during germinal stages VI-X. In NOA testes, mRNA expression of H3.5 (H3F3C) was significantly reduced compared with other H3 histone family members, and expression of H3.5 was significantly lower than that in OA. Additionally, the number of H3.5-positive germ cells was higher in hypospermatogenesis or late maturation arrest than in early maturation arrest in NOA testes (p < 0.01). A significant positive correlation was observed between H3.5 and PCNA expression (p < 0.05) but not TUNEL-positive cells, and expression of H3.5 was enhanced after hCG-based salvage hormonal therapy. Different from other testis-specific histones, which are often expressed during the histone-to-protamine transition during meiosis, H3.5 was expressed mainly in immature germ cells. H3.5 may play roles in DNA synthesis, but not apoptosis, and its expression is regulated by gonadotropins, indicating that such epigenetic regulations are important in normal spermatogenesis and spermatogenic disorders.
INTRODUCTION
Despite numerous studies of male infertility, most cases are categorized as idiopathic infertility, and the genetic causes for most patients remain largely unknown (Matzuk & Lamb, 2008) . Germ cells exhibit dramatic changes in cellular and nuclear structures, requiring dynamic chromatin alterations, and histones are replaced by transition proteins and eventually protamines to generate mature spermatozoa (Gaucher et al., 2010) . In this situation, not only genetic disorders but also epigenetic factors play crucial roles in impairing spermatogenesis. In fact, the group of genes that regulates dynamic epigenetic changes during spermatogenesis is significantly enriched with multiple nominally associated genes in testicular tissues in men with non-obstructive azoospermia (NOA) (Li et al., 2015) . An important mechanism for effectively undergoing spermatogenesis is germ cell type-specific post-translational modifications (PTMs) of histones, including acetylation, phosphorylation, methylation, and ubiquitination (Kimmins & Sassone-Corsi, 2005) . Together with histone PTMs, histone variants play important roles in spermatogenesis. Most testis-specific histone variants, including H1.6 (H1t), H1.9 (H1LS1), TH2A, H2B.1 (TH2B), H3.4, H3.5, H3t, and H4t, are expressed in a germ cell type-specific manner in spermatocytes and spermatids (Sun & Qi, 2014) . However, the mechanisms of regulation of epigenetic changes and the functional roles of these histone variants during spermatogenesis are not fully understood.
Eight variants of H3, H3.1, H3.2, H3.3, H3T (H3.4), H3.5, H3.X, H3.Y, and CENP-A (CenH3), have been found in humans. Among them, H3.5 is specifically expressed in the seminiferous tubules of human testes (Schenk et al., 2011) , mainly in spermatogonia and primary spermatocytes (Urahama et al., 2016) . H3t is synthesized in spermatogonia and remains detectable in spermatocytes and early spermatids (Trostle-Weige et al., 1984) . Despite that the other H3 variants are localized in all stages of germ cell types, these two H3 variants are thought to be involved in cellular proliferation and development by opening the chromatin structure as we recently reported (Ueda et al., 2017) .
Histone H3.5 is encoded on human chromosome 12p11.21 as the H3F3C gene, and its mRNA is highly expressed in seminiferous tubules (Schenk et al., 2011) . Recently, we reported that H3.5 localizes in spermatogonia and the primary spermatocyte, and the crystal structure of the H3.5 nucleosome is unstable because the H3.5-specific Leu 103 residue reduces the hydrophobic interaction with histone H4 (Urahama et al., 2016) . In addition, chromatin immunoprecipitation coupled with sequencing analysis revealed that H3.5 accumulated around transcription start sites (TSSs) (Urahama et al., 2016) , but its role in human spermatogenesis remains poorly understood. H3.5 accumulates around TSSs revealed by chromatin immunoprecipitation coupled with sequencing analysis (Urahama et al., 2016) , but its role in human spermatogenesis remains poorly understood. To further investigate the role and regulatory mechanisms of H3.5 in human spermatogenesis, we conducted an immunohistochemical analysis of human testes with normal spermatogenesis, various spermatogenic disorders and pharmacological manipulations.
MATERIALS AND METHODS

Patients
We retrospectively reviewed the records of consecutive male patients with NOA and obstructive azoospermia (OA) who underwent microdissection testicular sperm extraction (micro-TESE) between August 2012 and July 2016. All diagnostic and surgical procedures were performed by one of the authors (K.S.). After centrifugation, azoospermia was diagnosed at least twice. Testicular biopsy samples were obtained from a representative site from 60 men with NOA and were sent for histological analyses and RNA extraction. We excluded following conditions: chromosomal abnormities, such as Klinefelter syndrome, extremely small testes (<4 mL), such as varicocoele and cryptorchidism, and life-threatening diseases. We used 23 testicular biopsy specimens from men with OA, whose Johnsen's score count was greater than 9, as controls. Two patients with prostate cancer who underwent androgen deprivation therapy using a gonadotropin-releasing hormone (GnRH) antagonist and anti-androgen underwent castration; these testicular samples were used as gonadotropin-deficient samples.
For men with NOA in whom spermatozoa could not be obtained by micro-TESE, salvage hormonal therapy (Shiraishi et al., 2012) starting trice subcutaneous self-injections of 5000 IU of hCG (Gonadotropin; ASKA Pharmaceutical, Tokyo, Japan) and recombinant human FSH (rhFSH) (GONAL-F; Merck Serono, Geneva, Switzerland) (150 IU, trice weekly for 2 months prior to the second micro-TESE) was performed if the patients desired. After the purpose of this study was explained, informed consent from all patients and ethical approval were obtained. The study protocol was approved by the ethics committee of the Institutional Review Board (D42-120522), and all patients provided written informed consent before sampling of testicular tissues.
Quantitative RT-PCR mRNA was immediately extracted from biopsied samples, and cDNA synthesis was performed with Primescript Reverse Transcriptase and a dT primer (Takara Bio Inc., Kusatsu, Shiga, Japan). Quantitative RT-PCR (qPCR) was performed as previously described (Harada et al., 2015) . Primers used for qPCR are listed in Table S1 . qPCR data were normalized to Eef1a1 expression levels and presented as the mean AE standard deviation of three independent experiments.
Immunohistochemistry
The biopsy samples were fixed in Bouin's solution, embedded in paraffin, and 5-lm serial sections were prepared. After blocking non-specific with rabbit serum, the slides were incubated with anti-H3.5 monoclonal antibody (1 : 100 dilution) (Urahama et al., 2016) and an H3.5-specific synthetic peptide (TKAARKSTPSTCGVKPHRYRC) coupled to keyhole limpet hemocyanin. The percentage of H3.5-positive spermatogonia, primary spermatocytes/total spermatogonia and primary spermatocyte percentage were calculated. The sections were incubated with a rabbit polyclonal anti-histone H3 (1 : 100) antibody that specifically detects endogenous levels of total histone H3 protein (FL-136; Santa Cruz Biotechnology, Dallas, TX, USA) and a primary antibody against proliferating cell nuclear antigen (PCNA) (PC10; Santa Cruz, at a dilution of 1 : 500, Dallas, TX, USA) for 24 h at room temperature and were visualized using the avidin-biotin complex method. The sections were then counterstained with hematoxylin. The primary antibody was omitted in the negative controls. The spermatogonial PCNA-labeling index (LI) was calculated for each tubule as follows: PCNA-positive spermatogonia/total spermatogonia per tubule. Stage-specific quantification with the classical Clermont classification Russell et al., 1990) was performed in 10 seminiferous tubules for each stage of the 12 seminiferous epithelial cycles.
Statistical analysis
A software program (GraphPad InStat 3, La Jolla, CA, USA) was used for statistical analysis. Data are expressed as the mean AE standard deviation (SD). A Mann-Whitney t-test was used to determine the significance of differences among the groups. A paired t-test was used to examine the significance of differences of H3.5 expression before and after salvage hormonal therapy. Spearman rank correlation coefficients were calculated to examine the association between the expression of H3.5 and clinicohistological parameters. A value of p < 0.05 was considered statistically significant.
RESULTS
The mean AE SD for age, testicular volume, LH, FSH, testosterone, and PCNA-L.I. for the control (n = 23), NOA (n = 60), and prostate cancer (n = 2) groups are shown in Table 1 . Significant differences were found for the testicular volume, LH, FSH, testosterone, and PCNA-L.I. values between the control and NOA/prostate cancer groups (p < 0.0001). Spermatogenesis was observed in all control samples, whereas hypospermatogenesis (n = 6, 10%), maturation arrest (n = 22, 37%), and Sertoli cells only (SCO) (n = 32, 53%) were observed in NOA samples. The histopathology showed arrested maturation in prostate cancer samples with the administration of a GnRH antagonist and antiandrogen (Table 1) .
To compare the mRNA expression levels of H3.5 and H3.3, qPCR of H3F3C, H3F3A, and ACTB, which correspond to H3.5, H3.3 and beta-actin, respectively, was performed and adjusted to the expression of eukaryotic translation elongation factor 1 epsilon-1 (EeF1e1) (Fig. 1) . The expression of H3F3C was obviously decreased in men with NOA compared with that in the control group. The expression level of H3F3A was not different between these groups.
To assess the localization pattern of histone H3.5 in normal spermatogenesis, we conducted immunohistochemistry using an anti-H3.5 antibody. The purity and specificity of the antibody were shown in our previous study (Urahama et al., 2016) . As shown in Fig. 2 , the nuclei of most germ cells, especially spermatogonia and preleptotene-and leptotene-stage primary spermatocytes, were stained in a stage-dependent manner (Fig. 2) . No immunoreactivity was observed in negative control samples (data not shown), and H3.5 protein was not detected in postmeiotic cells or mature spermatozoa. Stages IV-X of the seminiferous epithelium cycle, which contain many preleptotene-and leptotene-stage primary spermatocytes, revealed a strong signal for H3.5 (Fig. 2D) . No tendency in the localization of H3.5-positive spermatogonia was observed during any of the stages.
The H3.5 expression levels were analyzed using samples from testes that exhibited normal spermatogenesis (Fig. 3A-C) , maturation arrest (Fig. 3D-F) , and SCO ( Fig. 3G-I ) and from testes of prostate cancer patients with gonadotropin suppression (Fig. 3J-L) . In all of the nuclei of the germ cells, Sertoli and Leydig cells were positive for a pan-H3 antibody (Fig. 3B ,E,H,K), whereas the localization of H3.5 was restricted to the spermatogonia and primary spermatocytes (Fig. 3A,D,G,J) . No immunoreactivity of H3.5 in was observed SCO and patients with prostate cancer, and the differences in the significantly lower in expression levels were significant (Fig. 4A) . To support this result, H3.5-positive cells/the number of spermatogonia and primary spermatocyte was significantly lower in maturation arrest than those in hypospermatogenesis and normal spermatogenesis (Fig. 4B) . There was no apparent difference in the intensity of immunoreactivity of H3.5 among the groups, but it was not quantified. PCNA was expressed at all stages of seminiferous tubules in the control testes. PCNA-positive nuclei were detected mainly in the spermatogonia and primary spermatocytes. 
EEF1A1)
Relative expression (Normalized to EEF1A1) Figure 1 Quantitative RT-PCR of H3F3C (A), H3F3A (B), and ACTB (C), which represents H3.5, H3.3, and beta-actin, respectively, adjusted by the expression of eukaryotic translation elongation factor 1 epsilon-1 (Eef1a1). NOA, non-obstructive azoospermia; OA, obstructive azoospermia.
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Expression of PCNA was also decreased in samples that exhibited maturation arrest and SCO and samples from prostate cancer patients (Fig. 3C,F,I ,L). H3.5 expression was significantly correlated with PCNA expression in control (p < 0.001) and NOA (p < 0.05) cases and was observed to be significantly correlated with testicular volume (p < 0.05) in control cases (Table 2) . In samples from patients who underwent hCG/FSH-based salvage hormonal therapy, the expression of H3.5 was significantly increased after hormonal therapy (Fig. 5 , p < 0.05), whereas gonadotropin suppression decreased H3.5 expression (Fig. 4) .
DISCUSSION
Although many studies have examined the localization and function of histone variants and their PTMs in human testes, precise investigations regarding the germinal stage and various human pathologic conditions are rare. Using a newly synthesized H3.5 antibody and human testicular samples, this study revealed that men with NOA exhibit overtly decreased expression of H3.5 compared with those with OA. H3.5 localizes in transcriptionally active spermatogonia and primary spermatocytes and is potentially involved in active DNA synthesis, as indicated by PCNA expression. Furthermore, H3.5 expression is thought to be regulated by gonadotropins because expression of H3.5 was decreased during gonadotropin deprivation and increased by stimulation with gonadotropins. These findings suggest that gonadotropin regulation of H3.5 plays an important role during the mitotic phase of spermatogenesis (Fig. 6 ). H3.5 is one of various epigenetic factors thought to be involved in human spermatogenesis. A cumulative understanding of each histone variant may provide insights into the pathophysiology of spermatogenic disorders and suggest therapeutic options for idiopathic male infertility.
During the mitotic and meiotic phases, several histone variants are present from spermatogonia until sperm maturation, while some variants are only present in haploid spermatids before histone-to-protamine replacement (Orsi et al., 2009) . To analyze the function of H3.5, an investigation of the spatial and temporal localization of H3.5 was first conducted. Testicular samples from patients with OA whose Johnsen's score count was greater than 9 were used as controls for normal spermatogenesis. Consistent with the observation reported by Schenk et al. (2011) , indicating that mRNA localization of H3.5 was an annular signal within the seminiferous tubules, H3.5 mRNA was present in human testes (Fig. 1) and was expressed mainly during the mitotic phase of germ cells (Figs 2 & 3) . Further investigation of the cell types and germinal stages showed that H3.5 was mainly expressed in the spermatogonia of all germinal stages and seminiferous tubules that contain preleptotene-and leptotene-stage primary spermatocytes (Fig. 2) , indicating its role in preparing the proper chromatin structures for events before or during the first meiotic cell division, which is one of the major roles for these cells. In spermatogonia, self-renewal ensures a constant supply of primary spermatocytes; many distinct genes have been identified with specific expression profiles that are thought to be influenced by histone PTMs (Khalil & Wahlestedt, 2008) . In addition to PTMs, the cell type-and stage-specific incorporations of different histone variants may play a role in the maturation of sperm chromatin. As another H3 variant, H3.3 is observed in the mouse seminiferous tubules, especially in spermatogonia and leptotene spermatocytes (Bramlage et al., 1997) . Yuen et al. (2014) showed that targeted disruption of H3f3b, a gene associated with H3.3, resulted in a number of phenotypic abnormalities, including a reduction in H3.3 histone levels, Figure 2 The representative immunostaining of the nuclei of pre-leptotene primary spermatocyte (pL) at stage V (A, 9400), leptotene primary spermatocyte (L) at stage X (B, 9400), and Ad spermatogonia (Ad) at stage XII seminiferous tubules (C, 9400) with the anti-H3.5 antibody in control testes. The stage-dependent expression of H3.5 is shown (D) subdivided by spermatogonia (black bars) and primary spermatocyte, mainly in preleptotene and leptotene stage (shaded bars). [Colour figure can be viewed at wileyonlinelibrary.com].
leading to male infertility, as well as abnormal spermatozoa and testes morphology. These observations may support that H3.5 and H3.3 share overlapping functions; however, the mRNA levels of H3.3 were not different between the control and NOA groups (Fig. 1) , indicating a more pivotal role of H3.5 during spermatogenesis. Although disruption of H3t (Ueda et al., 2017) Figure 4 The expression of H3.5 in spermatogonia and primary spermatocyte categorized by the diagnosis (A) and histological appearance (B). † and * indicate significant differences of p < 0.01 and p < 0.0001, respectively, compared to obstructive azoospermia (A) or normal spermatogenesis (B).
162 Andrology, 2018, 6, 158-165 respectively, it is still unclear whether decreased expression of H3.5 is a cause or a result of impairment of spermatogenesis. Lack of the expression of H3.5 in rodents prevents investigations using genetically modified animals, and the ultimate spermatogenic function remains unknown. In fact, the ratio, but not the absolute number of spermatogonia/primary spermatocytes, is decreased in testes with NOA (Fig. 4) , indicating that decreased expression of H3.5 per se may be involved in the deterioration of cellular function. Using limited human testicular samples, H3.5 expression was investigated in terms of DNA synthesis indicated by PCNA expression. Based on the microscopic appearance of the chromosomal material, the primary spermatocyte stage was subdivided into preleptotene, leptotene, zygonema, pachynema, diplonema, and diakinesis. Following DNA synthesis during the interphase, the chromosomes start to condense during the leptotene stage, following the paring of homologous chromosomes that commences in the zygotene stage. In this study, H3.5 localization was shown in spermatogonia, preleptotene, and leptotene spermatocytes (Fig. 2) . Thus, the close relationship between H3.5 and PCNA expression (Fig. 3, Table 2 ) demonstrates that H3.5 may be involved, at least in part, in active DNA synthesis during the S-phase. The precise interaction between H3.5 and PCNA expression is under investigation. In fact, all PCNA-positive cells are not H3.5-positive, and transversely, all H3.5-positive cells are not PCNA-positive. There are several hypotheses to explain these observations: (i) presence of the other factors regulating PCNA expression, (ii) time-lag between the expressions of H3.5 and PCNA. We have shown that close hydrophobic interactions are not observed around the Leu103 residue in the H3.5, leading to the unstable property of the DNA. In addition, the ChIP sequence revealed that H3.5 was enriched around TSSs independent of its expression level, whereas H3.5 was incorporated into both active and silent genes (Schenk et al., 2011) . The relationships between these unique characteristics of H3.5 and spermatogenic DNA synthesis are still unclear and require further investigation. Recently, we showed that the function of H3t is essential for the initial step of spermatogenesis and is required for spermatogonia (i.e., spermatogenic stem cells) to enter differentiation (Ueda et al., 2017) . In addition to H3.5, H3t plays a role in the early stage of spermatogenesis, mainly at the premeiotic differentiation and/or replication stage, and H3t deficiency leads to azoospermia. Similarities in localization and the amino acid sequences of H3.5 and H3t suggest compensative functions during the initial steps of spermatogenesis. Although accumulating evidence suggests that regulation of PTMs of the H3 family leads to germ cell apoptosis, defective spermiogenesis, and infertility (Peters et al., 2001; Okada et al., 2007; Tachibana et al., 2007; Liu et al., 2010; Iwamori et al., 2011) , H3.5 PTMs are completely unknown. Testicular samples from a variety of clinical backgrounds showed that hormonal regulation of H3.5 expression could be observed in spermatozoa as alterations of 'chromatin condensation, the transcriptome, and the proteome', indicating that deficits of both testosterone and FSH differentially affect the process of sperm chromatin remodeling. Physiological changes of gonadotropin did not associate with H3.5 expression (Table 2 ), but drastic changes of gonadotropin such as gonadotropin deprivation (Figs 3 & 4) and stimulation with gonadotropins (Fig. 5) suggest that expression of H3.5 is thought to be regulated, at least in part, by gonadotropins. It has long been known that FSH potentially regulates spermatogonial development via control of proliferation and/or apoptosis (McLachlan et al., 1995; Shetty et al., 1996; Meachem et al., 1999) . FSH acts to support spermatogonial and spermatocyte populations and maturation through Sertoli cells, and FSH is required to reinitiate and quantitatively maintain normal sperm production after hormonal manipulation (McLachlan et al., 1995; Shetty et al., 1996; Meachem et al., 1999) . Meachem et al. (1999) previously demonstrated a 30% reduction in spermatogonial number and a slight reduction in preleptotene spermatocyte populations resulting from this treatment using the experimental model of FSH suppression via administration of an FSH antibody to adult rats. In humans, we observed increased expression of Sertoli cell androgen receptors after FSH stimulation, which led to increased expression of PCNA in spermatogonia and primary spermatocytes (Kato et al., 2014) . Indirect paracrine and juxtacrine regulations by Sertoli cells are thought to be involved. Genetic models of hypogonadism may prove these hypotheses, but H3.5 is observed only in human. One limitation of the clinical study was that the dose used in biopsy samples was limited; we could not use testicular tissues from preadolescent samples where gonadotropin stimulation is still low, whereas age-dependent expression of histone H3 variants is observed in mouse spermatogenesis (Sun & Qi, 2014) . Based on our result that gonadotropin deprived samples showed very low H3.5 ratio, the expression of H3.5 may be gonadotropindependent.
There are several potential limitations of this study. First, histone PTMs, such as acetylation, methylation, ubiquitylation, and phosphorylation, have emerged as the main players in epigenetic regulatory mechanisms, but this study examined only the expression of proteins. Using human testicular samples, Kleiman et al. (2008) reported that the reduced percentage of spermatogonia with histone-H4 hyperacetylation and lysine-12 acetylation may contribute to the lower sperm production observed in mixed atrophy. Understanding how H3.5 is regulated and which genes H3.5 regulates is necessary. Second, the variety of samples is still limited. If we can obtain, for example, fetal, pre-pubertal, male hypogonadotropic hypogonadism and aged samples, the functional and regulatory aspects may become clearer.
Ethical problems in obtaining these samples inhibit further investigation. Because H3.5 is present only in human, we cannot use gene-modified animals to investigate its precise roles during spermatogenesis. Alternatively, we started single cell transcriptome analysis using each cell types from normal and infertile testes.
As a continuation of our previous observations regarding the structural and molecular properties of H3.5, this study extends our understanding of epigenetic regulation of human spermatogenesis and could be a resource for the investigation of spermatogenic disorders. Gene-modified animal studies of H3 variants suggest a role of H3t and H3.3 in spermatogenesis. H3.5 and these histone variants play important roles in spermatogenesis in humans, and this information will provide diagnostic and therapeutic strategies to manage cases of male infertility in the clinical setting.
